The Phase 1/2 study evaluated a two-dose regimen of Moderna’s investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response.

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.

The department is canceling 22 projects including awards to Moderna for bird flu vaccine development, contracts with Emory University and rejecting proposals from Pfizer and Sanofi.

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

The Phase 1/2 study evaluated a two-dose regimen of Moderna’s investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response.

The department is canceling 22 projects including awards to Moderna for bird flu vaccine development, contracts with Emory University and rejecting proposals from Pfizer and Sanofi.

The vaccine’s efficacy was 26.6% higher than GSK’s flu shot in the overall study population that covered over 40,000 participants across 11 countries.